AmerisourceBergen Declares Quarterly Dividend
February 09 2016 - 6:45AM
Business Wire
The Board of Directors of AmerisourceBergen Corporation (NYSE:
ABC) today declared a quarterly dividend of $0.34 per common share,
payable March 7, 2016, to stockholders of record at the close of
business on February 22, 2016.
About AmerisourceBergen
AmerisourceBergen is one of the largest global pharmaceutical
sourcing and distribution services companies, helping both
healthcare providers and pharmaceutical and biotech manufacturers
improve patient access to products and enhance patient care. With
services ranging from drug distribution and niche premium logistics
to reimbursement and pharmaceutical consulting services,
AmerisourceBergen delivers innovative programs and solutions across
the pharmaceutical supply channel in human and animal health. With
over $135 billion in annual revenue, AmerisourceBergen is
headquartered in Valley Forge, PA, and employs approximately 18,000
people. AmerisourceBergen is ranked #16 on the Fortune 500 list.
For more information, go to www.amerisourcebergen.com.
AmerisourceBergen's Cautionary Note Regarding Forward-Looking
Statements
Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Words such as "expect," "likely," "outlook,"
"forecast," "would," "could," "should," "can," "will," "project,"
"intend," "plan," "continue," "sustain," "synergy," "on track,"
"believe," "seek," "estimate," "anticipate," "may," "possible,"
"assume," variations of such words, and similar expressions are
intended to identify such forward-looking statements. These
statements are based on management's current expectations and are
subject to uncertainty and change in circumstances. These
statements are not guarantees of future performance and are based
on assumptions that could prove incorrect or could cause actual
results to vary materially from those indicated. Among the factors
that could cause actual results to differ materially from those
projected, anticipated, or implied are the following: competition;
industry consolidation of both customers and suppliers resulting in
increasing pressure to reduce prices for our products and services;
changes in pharmaceutical market growth rates; price inflation in
branded and generic pharmaceuticals, and price deflation in
generics; declining economic conditions in the United States and
abroad; financial market volatility and disruption; substantial
defaults in payment, material reduction in purchases by or the
loss, bankruptcy or insolvency of a major customer; the loss,
bankruptcy or insolvency of a major supplier; changes to the
customer or supplier mix; the retention of key customer or supplier
relationships under less favorable economics or the adverse
resolution of any contract or other dispute with customers or
suppliers; changes in any of the economic models used by any of our
suppliers to set pricing and/or other terms for the purchase of
pharmaceuticals; interest rate and foreign currency exchange rate
fluctuations; the disruption of AmerisourceBergen's cash flow and
ability to return value to its stockholders in accordance with its
past practices; risks associated with the strategic, long-term
relationship between Walgreen Boots Alliance, Inc. and
AmerisourceBergen, including with respect to the pharmaceutical
distribution agreement and/or the global sourcing arrangement;
risks associated with the potential impact on AmerisourceBergen's
earnings per share resulting from the issuance of the warrants to
subsidiaries of Walgreen Boots Alliance, Inc. (the "Warrants");
AmerisourceBergen's inability to fully implement its hedging
strategy to mitigate the potentially dilutive effect of the
issuance of its common stock in accordance with the Warrants under
its special share repurchase program due to its financial
performance, the current and future share price of its common
stock, its expected cash flows, competing priorities for capital,
and overall market conditions; changes in the United States
healthcare and regulatory environment; increasing governmental
regulations regarding the pharmaceutical supply channel and
pharmaceutical compounding; federal and state government
enforcement initiatives to detect and prevent suspicious orders of
controlled substances and the diversion of controlled substances;
federal and state prosecution of alleged violations of related laws
and regulations, and any related litigation, including shareholder
derivative lawsuits or other disputes relating to our distribution
of controlled substances; increased federal scrutiny and qui tam
litigation for alleged violations of fraud and abuse laws and
regulations and/or any other laws and regulations governing the
marketing, sale, purchase and/or dispensing of pharmaceutical
products or services and any related litigation; material adverse
resolution of pending legal proceedings; declining reimbursement
rates for pharmaceuticals; the acquisition of businesses that do
not perform as expected, or that are difficult to integrate or
control, including the integration of MWI and PharMEDium, or the
inability to capture all of the anticipated synergies related
thereto; managing foreign expansion, including non-compliance with
the U.S. Foreign Corrupt Practices Act, anti-bribery laws and
economic sanctions and import laws and regulations; malfunction,
failure or breach of sophisticated information systems to operate
as designed; risks generally associated with data privacy
regulation and the international transfer of personal data; changes
in tax laws or legislative initiatives that could adversely affect
AmerisourceBergen's tax positions and/or AmerisourceBergen's tax
liabilities or adverse resolution of challenges to
AmerisourceBergen's tax positions; natural disasters or other
unexpected events that affect AmerisourceBergen's operations; the
impairment of goodwill or other intangible assets, resulting in a
charge to earnings; errors in the production, labeling or packaging
of products compounded by our compounded sterile preparations (CSP)
business; and other economic, business, competitive, legal, tax,
regulatory and/or operational factors affecting AmerisourceBergen's
business generally. Certain additional factors that management
believes could cause actual outcomes and results to differ
materially from those described in forward-looking statements are
set forth (i) in Item 1A (Risk Factors) in the Company’s Annual
Report on Form 10-K for the fiscal year ended September 30, 2015
and elsewhere in that report and (ii) in other reports filed by the
Company pursuant to the Securities Exchange Act.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160209005358/en/
AmerisourceBergen CorporationBarbara Brungess,
610-727-7199bbrungess@amerisourcebergen.com
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From May 2023 to May 2024